Compare ASE Technology Holding Co Ltd (ASX) vs Heron Therapeutics Inc (HRTX) Price & Performance

ASE Technology Holding (ASX) trades at $39.56, up 5.23% today, showing strong momentum with three consecutive earnings beats. The stock maintains bullish technical signals with support at $38 and resistance at $40. Recent Q2 2026 results demonstrated robust growth in AI-driven semiconductor packaging demand, with the company increasing 2026 capital expenditure to $10.5 billion to expand capacity.

Outlook remains positive with 80% analyst buy ratings and projected revenue growth to $711.2 billion in 2026. Key risks include high valuation multiples (P/E 47.78) and significant capital investment requirements. The AI semiconductor boom provides substantial growth opportunity, though execution on expansion plans will be critical for sustained performance.

HRTX trades at $0.3507, up 6.21% in the last 24 hours, but technical indicators signal a bearish trend overall. The company reported Q2 2026 revenue of $37.7 million, missing estimates, with a net loss per share of $0.03. Despite a high gross profit margin of 70.07%, negative net income and cash flow from operations highlight financial strain. Analyst consensus remains strongly bullish with 94.74% buy ratings, but recent news includes a Zacks Strong Sell designation on July 15, 2026.

The outlook is mixed: strong analyst support contrasts with weak earnings and bearish technicals. Investment opportunity lies in potential turnaround if revenue growth accelerates, but risks include persistent losses, competitive pressures, and reliance on financing activities. The stock faces significant downside if operational performance does not improve.